英文11
- 1. ADOPT Glycemic Durability of Rosiglitazone, Metformin, and Glyburide Monotherapy Number HbA 1c (%) BMI Subjects: Rosiglitazone 1,456 7.4 32.2 Metformin 1,454 7.4 32.1 Glyburide 1,441 7.4 33.2 Study Design: Randomized, double blind, controlled study US, Canada, & Europe Gly (7.5 mg bid); Met (1 mg bid); Rosi (4 mg bid) Median Follow-up: 4.0 years End Point: Monotherapy failure (FPG > 180 mg%) Kaplan-Meier analysis Kahn et al, NEJM 355:2427-43, 2006